Why Cannabis Brands Keep Getting Sued for Inflated THC Numbers

The label on the jar says 32% THC. The product inside, when independently tested, comes in at 18%. Not a rounding discrepancy. Not a measurement variance. A 14-percentage-point gap between the marketing number and the actual potency. The consumer paid premium pricing for premium potency that wasn't there.

This is happening across legal cannabis markets in the United States in 2026. The pattern is widespread enough that it has produced a growing wave of consumer protection lawsuits, class actions, and regulatory inquiries. The cases name specific brands. The cases cite specific lab fraud. The cases allege that the entire shelf-pricing structure of legal cannabis is built on potency numbers that are not what they claim to be.

This is the THC inflation story. This is why brands are getting sued. And this is why most of the legal cannabis you have purchased in recent years was probably not as potent as the label said.

How THC Got to Be the Number That Matters

Before legalization, consumers selected cannabis based on strain reputation, sensory cues (smell, look, density), price, and the recommendations of dealers or friends. THC percentage was a number that almost no one had access to and almost no one used as a primary purchasing criterion.

Legal cannabis introduced testing requirements that produced specific potency numbers on every product. The numbers became visible at retail. The numbers became one of the primary signals consumers used to compare products. The numbers became, increasingly, the dominant purchasing criterion at many dispensaries.

The market dynamics that followed were predictable. Consumers gravitated toward higher THC numbers, often based on the assumption that higher numbers meant better products. Retailers pricing structures responded, with higher-THC products commanding premium pricing. Cultivators and brands responded to the price signals by emphasizing THC potency in their products, marketing, and packaging.

Within a few years, THC percentage had become the dominant unit of consumer comparison and the primary driver of price differentiation. A 30%+ THC flower could command 40–60% premium pricing over a 20% THC flower of comparable strain and quality.

The problem was that the testing infrastructure producing the numbers was, in many cases, not capable of producing reliable measurements at the precision the market was relying on. And some of the operators in that infrastructure were actively manipulating the numbers.

The Science of THC Testing

Cannabis flower THC testing involves taking a sample of the cannabis, preparing the sample for analysis, running the sample through laboratory equipment (typically high-performance liquid chromatography, HPLC), and calculating the THC concentration based on the results.

Several variables in this process produce measurement variance.

Sampling. A sample of a few grams from a larger batch may not be perfectly representative of the batch. Cannabinoid distribution within and between plants can vary. Different sample selection produces different results.

Sample preparation. The procedures used to prepare the sample for analysis affect results. Decarboxylation handling, extraction efficiency, and other preparation variables all matter.

Equipment calibration. HPLC equipment requires careful calibration and maintenance. Calibration drift, equipment problems, and methodological inconsistencies all produce variance.

Analyst technique. Different analysts performing the same procedures may produce different results due to technique variations.

Calculation methodology. Different labs may use different calculation methods to arrive at the final reported THC percentage. Some labs report total THC (including THCA converted to THC), some report a different mathematical calculation, some report inconsistently across batches.

Even with optimal practices, cannabis flower THC measurements have inherent variance of several percentage points. With suboptimal practices — and many cannabis labs operate with substantially suboptimal practices — variance can be substantial.

The Inflation Patterns

Beyond legitimate measurement variance, several specific patterns of THC inflation have been documented in cannabis labs across multiple states.

Methodological inflation. Labs using calculation methods that systematically produce higher numbers than other methods. The labs may be technically following accepted procedures but selecting from among permissible procedures the ones that produce highest numbers.

Sample manipulation. Labs accepting samples from cultivators or brands that have been selected to produce high results, then reporting those results as if representative of the entire batch.

Equipment manipulation. Labs using equipment configurations that systematically produce higher results than properly calibrated equipment would produce.

Outright falsification. Labs reporting test results that are not based on actual testing — entered into systems to support cultivator/brand requests for higher numbers.

Race-to-the-top dynamics. Labs with stricter methodology lose business to labs with looser methodology because cultivators choose labs that produce numbers they want. The market structure rewards inflation.

The aggregate effect is that THC numbers reported on cannabis products in many markets systematically overstate actual potency. Independent verification testing, conducted by various researchers and organizations, has consistently found that reported THC percentages exceed actual potency by margins that often exceed 5 percentage points and sometimes exceed 10 percentage points.

The Lawsuits

Consumer protection litigation alleging THC inflation has emerged across multiple jurisdictions in recent years.

Class action consumer fraud cases. Consumers have filed class actions against specific cannabis brands alleging that THC potency claims on packaging were materially false. The cases typically allege violations of state consumer protection laws and seek damages, refunds, and injunctive relief. Several cases have produced settlements.

False advertising cases. Some lawsuits have framed the claims primarily as false advertising violations, alleging that cannabis brands made specific potency claims that were not supported by the products they sold.

Unfair competition cases. Some plaintiffs have framed claims as unfair competition violations, alleging that cannabis brands gained competitive advantage through false potency claims at the expense of competitors making more accurate claims.

RICO claims. A small number of cases have framed coordinated lab inflation as racketeering activity, with the labs and brands as participants in the racketeering enterprise. These cases face high legal hurdles but have produced significant attention.

The litigation is in early stages in most jurisdictions, with outcomes still developing. The aggregate trend is toward increasing litigation volume and increasing plaintiff success.

The Lab Cases

Beyond brand-focused litigation, regulatory and litigation actions against specific labs have produced documentation of inflation practices.

The New York OCM action against Keystone State Testing. As detailed in our cannabis recall coverage, Keystone State Testing was found to have falsely reported test results for 54 product lots, including reporting Aspergillus contamination as negative and potentially other testing failures. The state has revoked or restricted the lab's operating authority.

Various state regulator enforcement actions. Cannabis regulators in California, Florida, Pennsylvania, and other states have taken enforcement actions against specific labs for testing irregularities. The actions have included license suspensions, monetary penalties, and criminal referrals.

Whistleblower-driven cases. Several cases have been initiated based on whistleblower disclosures by current or former lab employees who documented inflation practices internally. Whistleblower protections in some states have facilitated these cases.

Industry self-regulatory actions. Some industry organizations have taken steps to identify and exclude labs with documented integrity issues, though enforcement has been inconsistent.

The pattern across cases is consistent: lab integrity issues are real, widespread, and connected to the commercial pressure created by the consumer market's THC fixation.

What Brands Are Doing About It

Cannabis brands have responded to the THC inflation issue in several ways.

Some have doubled down on inflation. Brands competing in markets where high THC numbers drive sales have continued to work with labs that produce favorable numbers, treating the inflation as a competitive necessity.

Some have shifted to alternative differentiation. A growing number of brands have de-emphasized THC numbers in their marketing in favor of strain genetics, terpene profiles, cultivation practices, and other quality indicators that are harder to manipulate. These brands argue (correctly) that THC percentage is not the best measure of cannabis quality.

Some have pursued lab transparency. Some brands have invested in lab integrity programs, including using multiple labs for verification, publishing detailed Certificate of Analysis data, and inviting independent verification.

Some have begun pursuing the labs and brands they perceive as inflating. Cannabis competitive litigation has begun including allegations that competitor inflation has unfairly disadvantaged honest operators.

The fragmentation of brand response to inflation reflects the broader tension between competitive pressure to inflate and integrity pressure not to inflate. The brands willing to accept lower THC numbers in exchange for accuracy face commercial disadvantage. The brands willing to inflate face increasing legal exposure.

What Consumers Should Know

For consumers, the THC inflation issue suggests several specific shifts in how to evaluate cannabis products.

Stop using THC percentage as the primary purchasing criterion. The numbers on labels are not reliable comparison points. Two products with reported 28% and 24% THC may actually have similar potency once measurement variance and inflation are accounted for.

Pay attention to terpene profiles when available. Terpenes (the aromatic compounds in cannabis) substantially affect the experience of consumption. Terpene profiles are harder to inflate than THC percentages and provide more meaningful comparison information.

Consider strain genetics and cultivation practices. Different cannabis strains produce meaningfully different effects independent of THC percentage. Cultivation practices (organic vs. conventional, indoor vs. outdoor, hand-trimmed vs. machine-trimmed) affect quality in ways that THC numbers do not capture.

Try products in moderation before forming opinions. Your subjective experience of a product is more reliable than the label claims. Trying a small amount of a new product allows you to assess actual effects rather than relying on the marketing.

Patronize brands that have built integrity reputations. Brands that have publicly committed to lab integrity and have invested in verification infrastructure deserve consumer support.

Patronize dispensaries that prioritize transparent product information. Some dispensaries provide detailed product information including third-party verification results, COA data, and other information beyond the brand-supplied claims. These dispensaries support more informed consumer decisions.

Recognize the price-quality relationship is not what the labels suggest. A "premium" product priced at premium levels because of high THC numbers may not actually be a higher-quality product. Price differentials based on THC inflation are not capturing actual quality differences.

What Reform Looks Like

The THC inflation crisis is, in significant part, fixable through specific policy and market interventions.

Stronger lab integrity enforcement. State cannabis regulators with authority to license, audit, and revoke cannabis labs need to use that authority more aggressively. Regular auditing, blind sampling, and proactive enforcement reduce inflation incentives.

Standardized testing methodology. Mandatory standardization of THC testing methodology — sample selection, preparation, calculation methods — would reduce the methodological variance that allows inflation. Several states have moved toward standardization with mixed implementation.

Required third-party verification. Some products could be required to undergo verification testing by independent labs before market release, with discrepancies between cultivator/brand-selected lab results and verification lab results triggering enforcement action.

Mandatory disclosure of lab selection. Cannabis products could be required to disclose which lab conducted the testing, allowing consumers to recognize and avoid labs with poor integrity reputations.

Consumer education campaigns. State regulators and industry organizations could invest in consumer education that addresses THC inflation and provides alternative product evaluation criteria. Reduced consumer focus on THC numbers reduces the commercial incentive for inflation.

Stronger consumer protection enforcement. Existing consumer protection laws apply to cannabis. State attorneys general and consumer protection agencies should pursue THC inflation cases with the same rigor they would pursue equivalent fraud in other industries.

The Bottom Line

The THC numbers on the cannabis you have been buying are not, in many cases, what they claim to be. Lab integrity issues are documented. Brand inflation is documented. Consumer harm is documented. Litigation is accumulating. Regulatory attention is growing.

The market structure that produced this — consumer fixation on THC numbers, dispensary pricing based on THC, lab competition that rewards inflation — is changeable. The question is whether the changes will be driven by regulatory action, by litigation outcomes, by industry self-discipline, or by consumer behavior shifts.

In the meantime, the cannabis you bought yesterday for premium pricing because the label said 32% THC was probably not actually 32% THC. The brand that sold it to you may be defending itself in litigation soon. The lab that tested it may be the subject of regulatory action.

That is the legal cannabis market that exists in 2026. It is not the market the legalization advocates promised. Honest acknowledgment of the gap is the prerequisite for closing it.

---

Internal links:

• Fake Lab Results: How Cannabis Testing Labs Are Lying to Consumers →
• Every Cannabis Recall in 2025-2026: A Running List →
• How to Tell If Your Dispensary Is Selling You Old Weed →